GenSight Biologics settles EUR 1.69 million private placement share issuance

GenSight Biologics announced the settlement of a EUR 1.69 million fundraising. The transaction involved the issuance of 14.15 million ordinary shares admitted to trading on Euronext Paris. It also included 4.27 million prefunded share subscription warrants, exercisable into 4.27 million additional ordinary shares. In addition, 18.42 million investor share subscription warrants were issued, exercisable into 9.21 million ordinary shares. The prefunded and investor warrants will not be admitted to trading on any stock exchange.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gensight Biologics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260317575491) on March 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.